Beijing Hotgen Biotech Co Ltd (688068) - Total Liabilities
Based on the latest financial reports, Beijing Hotgen Biotech Co Ltd (688068) has total liabilities worth CN¥278.25 Million CNY (≈ $40.72 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Beijing Hotgen Biotech Co Ltd generate cash to assess how effectively this company generates cash.
Beijing Hotgen Biotech Co Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Beijing Hotgen Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Beijing Hotgen Biotech Co Ltd (688068) asset resilience to evaluate the company's liquid asset resilience ratio.
Beijing Hotgen Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing Hotgen Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥2.27 Billion |
|
Hefei Jianghang Aircraft Equipment Corporation Ltd
SHG:688586
|
China | CN¥1.14 Billion |
|
Killam Apartment Real Estate Investment Trust
TO:KMP-UN
|
Canada | CA$2.44 Billion |
|
Zhejiang Jiangshan Chemical Co Ltd
SHE:002061
|
China | CN¥60.64 Billion |
|
Paradox Interactive AB (publ)
ST:PDX
|
Sweden | Skr671.30 Million |
|
dentalcorp Holdings Ltd
TO:DNTL
|
Canada | CA$1.70 Billion |
|
Vietnam Export Import Commercial Joint Stock Bank
VN:EIB
|
Vietnam | ₫247.26 Trillion |
|
Encore Capital Group Inc
NASDAQ:ECPG
|
USA | $4.36 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Beijing Hotgen Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Beijing Hotgen Biotech Co Ltd (688068) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Hotgen Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Hotgen Biotech Co Ltd (2016–2024)
The table below shows the annual total liabilities of Beijing Hotgen Biotech Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥251.77 Million ≈ $36.84 Million |
+24.29% |
| 2023-12-31 | CN¥202.56 Million ≈ $29.64 Million |
-62.87% |
| 2022-12-31 | CN¥545.59 Million ≈ $79.84 Million |
-29.24% |
| 2021-12-31 | CN¥771.01 Million ≈ $112.82 Million |
+395.12% |
| 2020-12-31 | CN¥155.72 Million ≈ $22.79 Million |
+103.89% |
| 2019-12-31 | CN¥76.37 Million ≈ $11.18 Million |
+34.75% |
| 2018-12-31 | CN¥56.68 Million ≈ $8.29 Million |
+102.42% |
| 2017-12-31 | CN¥28.00 Million ≈ $4.10 Million |
-3.91% |
| 2016-12-31 | CN¥29.14 Million ≈ $4.26 Million |
-- |
About Beijing Hotgen Biotech Co Ltd
Beijing Hotgen Biotech Co., Ltd. engages in the research, development, manufacture, and sale of medical and public safety inspection products of in-vitro diagnostic products in the field of biomedicine. It offers public safety solutions such as drug tasting, customs disease control, bioterrorism and food safety solutions. The company also provides clinical diagnostics and product solutions, inclu… Read more